U.S. Hotel and Resort REITs Stock News

NasdaqGM:MNKD
NasdaqGM:MNKDBiotechs

MannKind (MNKD) Stock Faces Margin Strain Despite Stronger Product Sales

MannKind stock came into this earnings print already under pressure, and the latest numbers knocked it another 5% lower to US$3.89. The move appears driven less by revenue and more by the profit squeeze. Q2 revenue reached US$109.4m, while the company reported a GAAP net loss of US$19.0m, as launch spending and higher operating costs weighed on results. For a biotech trying to build around Afrezza and Furoscix, this quarter tested investor patience. The core question now is whether this level...
NYSE:GNW
NYSE:GNWInsurance

Genworth Financial (GNW) Stock Holds Firm As LTC Volatility Clouds Enact Strength

Genworth Financial’s stock barely flinched after earnings, up just 0.2% to US$9.71, yet the quarter told a more complicated story than the price suggests. The headline was a profitable quarter on paper, with US$47 million in net income and adjusted operating income ex Closed Block of US$112 million. The real pressure point sat in the legacy long term care book, where a US$110 million adjusted operating loss from the Closed Block reminded investors that reserve volatility still bites, even as...
NYSEAM:GROY
NYSEAM:GROYMetals and Mining

Gold Royalty (GROY) Stock Ignores Profit Turn As Concentration Questions Linger

Gold Royalty stock barely flinched after earnings, slipping less than 1% to about US$2.87, even though the headline was anything but quiet. The company moved further into profit with Q2 net income of US$1.8 million on revenue of US$6.7 million, backed by record first half revenue of US$17.3 million and adjusted earnings before interest, tax, depreciation and amortization that reached US$12.6 million. The calm share price masks a sharper shift in sentiment. Investors are treating this as...
NasdaqGS:BBSI
NasdaqGS:BBSIProfessional Services

Barrett Business Services (BBSI) Stock Price Sinks As Margin Pressure Hits Earnings

Barrett Business Services just saw its stock drop 17.5% in a single session to US$33.09. That is a sharp reset for a company that came into this earnings print with a trailing P/E of 23.2x and a reputation for high quality earnings. The market is clearly punishing one thing above all else: profitability is under pressure. Q2 diluted EPS was US$0.52 compared with US$0.70 a year earlier, and management now expects 2026 gross margin to sit near 2.7% of gross billings. For a human capital and...
NasdaqGS:MKSI
NasdaqGS:MKSISemiconductor

MKS (MKSI) Stock Could Be 11% Undervalued On Cash Flow Strength

MKS stock has delivered a strong 208.6% return over the past three years, yet its valuation signals are mixed, with an intrinsic value estimate based on a Discounted Cash Flow (DCF) model pointing to upside while traditional market multiples lean expensive. That split leaves investors weighing a DCF that suggests the shares trade below intrinsic value against broader checks that are less supportive. The 208.6% three year return highlights how strongly the share price has already repriced, so...
NYSE:LB
NYSE:LBReal Estate

LandBridge (LB) Stock Price Leans On 89% Margin As Valuation Questions Persist

LandBridge walked into this earnings season with a premium P/E and a reputation as a high margin, fee based infrastructure play. The stock had already climbed over the past quarter, yet the market still punched it 6.3% higher to about $80 after the Q2 print. That reaction reflects one headline: cash generation and profitability looked strong enough to keep the rich valuation intact. The single story investors are trading on today is margin quality. LandBridge reported record Q2 revenue of...
NYSE:CL
NYSE:CLHousehold Products

Should Colgate-Palmolive (CL) Look Fully Valued After Q2 Results And Steady Guidance?

What Colgate-Palmolive’s Updated Guidance Means For Investors Colgate-Palmolive (CL) moved into focus after reporting second quarter 2026 results and keeping its full year outlook. Sales were higher year on year, while net income and earnings per share declined. See our latest analysis for Colgate-Palmolive. Colgate-Palmolive’s share price has climbed 19.71% year to date and is up 6.22% over the past 90 days, while the 1-year total shareholder return of 12.53% suggests steady long term...
NYSE:QGEN
NYSE:QGENLife Sciences

Qiagen (QGEN) Stock Faces An Execution Puzzle After Margin Rebound

Qiagen stock barely flinched after earnings, slipping just 0.5% to about US$41.70 even after a quarter that quietly reset the profit story. The company delivered Q2 net sales of US$535 million, slightly above its own outlook, and adjusted earnings per share of US$0.62, also ahead of guidance. That kept the trailing net profit margin near 19%, a sharp contrast with the much thinner profitability investors saw a year ago. For anyone thinking beyond today’s small price move, the real question...
NasdaqGS:PTON
NasdaqGS:PTONLeisure

Peloton (PTON) Stock May Still Look Stretched Despite Subscriber And Cash Flow Hopes

Peloton Interactive stock is trading in a way that sits awkwardly with its long term record, as a share price that closed at US$5.51 most recently comes after the stock declined about 95.1% over the past five years, while the current valuation checks still lean expensive rather than cheap. Over the last five years, Peloton Interactive has declined roughly 95.1%, which puts the current share price in the context of a very heavy long term drawdown for existing shareholders. Future growth in...
NasdaqGS:ZVRA
NasdaqGS:ZVRAPharmaceuticals

Zevra Therapeutics (ZVRA) Stock Jumps On Profitability While MIPLYFFA Concentration Lingers

Zevra Therapeutics stock jumped 12.8% to US$11.88 in the first full session after its Q2 release, a sharp move for a company often framed as a long duration rare disease bet rather than a quarter-to-quarter story. The headline this time is profitability with cash to back it. Zevra reported US$39.7m in revenue and US$8.8m in net income, while lifting its cash, equivalents and investments to about US$260m. The gap between a single strong quarter and the longer term thesis is where the real work...
NYSE:FCX
NYSE:FCXMetals and Mining

Copper Stocks to Watch as Electrification Demand Tightens Supply

Copper prices are hitting records as supply disruptions collide with the electrification push, from power grids to AI data centers. That mix is rewarding some companies linked to copper and pressuring others that rely on it as a key input. For investors, this creates a narrow window where the winners and losers can look very different. This article walks through 3 stocks closely exposed to this copper shock and why they matter now. Southern Peru Copper Corporation - Sucursal del Peru...
NasdaqGM:SYM
NasdaqGM:SYMMachinery

Symbotic (SYM) Stock Sinks As Profit Engine Gains Traction

Symbotic stock just took a 15% hit in a single session, yet the earnings print reads more like a company finding its profit engine than one falling apart. Revenue landed at about US$721 million, close to the top of guidance, while adjusted earnings before interest, tax, depreciation and amortization more than doubled to US$95 million and cleared expectations. For a warehouse automation specialist that had only recently turned the earnings corner, that combination of strong top line and...
NasdaqGS:BKR
NasdaqGS:BKREnergy Services

Hypermobile Data Center and LNG Equipment Orders Could Be A Game Changer For Baker Hughes (BKR)

In late July 2026, Dynamis Power Solutions and Venture Global LNG announced major orders for Baker Hughes equipment, including 76 NovaLT™16 gas turbines for hypermobile power generation and a comprehensive liquefaction package for Venture Global’s CP2 LNG project in Louisiana. These wins highlight Baker Hughes’ growing exposure to data center power needs and large-scale LNG infrastructure, underscoring the breadth of demand for its turbines, compressors, and related systems across digital...
NYSE:AFL
NYSE:AFLInsurance

Is Aflac’s (AFL) Community Leadership Push Hinting at a Deeper U.S. Premium Strategy Shift?

Aflac recently supported the United Way of the Chattahoochee Valley by providing a customized leadership development workshop, while analysts also highlighted that its second-quarter results were expected to benefit from growth in net earned premiums in the U.S. segment driven by higher sales. Beyond underscoring anticipated strength in its U.S. premium base, Aflac’s outreach shows how its internal leadership capabilities are being applied to strengthen community organizations. Next, we’ll...
NYSE:UHAL
NYSE:UHALTransportation

U Haul Holding (UHAL) Stock Sees Revenue Climb While Profit Margin Tightens

U-Haul Holding stock barely flinched, up about 1.4% on the day, even as the headline told a more complicated story. Q1 FY2027 brought solid revenue of US$1.68b and a return to profit, with basic earnings per share of US$0.63 after recent quarterly losses. Yet net income of US$122.9m sat below last year’s US$142.3m, and investors had to weigh that softer profit against evidence that the core moving and storage engine is still pulling in more dollars. The market reaction looked calm; the...
NasdaqGM:BLBD
NasdaqGM:BLBDMachinery

Blue Bird (BLBD) Stock Price Falls As Profit Surge Meets Durability Doubts

Blue Bird just delivered one of the sharpest disconnects of this earnings season. The stock dropped 14.2% to about US$66 after the Q3 report, even though the company reported US$517.2m in revenue and basic earnings per share of US$5.41. That is a large increase from earlier in the fiscal year and leaves the trailing P/E near 7.4x compared with a much higher machinery industry average. Coming into the report, Blue Bird shares had already been under pressure over the last month. This quarter...
NasdaqGS:ADUS
NasdaqGS:ADUSHealthcare

Is Stronger Earnings And Deleveraging-Fueled M&A Ambition Altering The Investment Case For Addus HomeCare (ADUS)?

In early August 2026, Addus HomeCare reported higher net income of US$27.61 million and diluted EPS of US$1.49 for the second quarter, alongside six‑month earnings growth versus the prior year, and outlined plans to pursue larger acquisitions supported by reduced bank debt of US$64.3 million. A distinctive takeaway is management’s focus on expanding personal care and selectively adding home health assets, using its strengthened balance sheet to deepen geographic coverage and relationships...
NYSE:CNR
NYSE:CNROil and Gas

Is Core Natural Resources (CNR) A Bargain As Earnings Recovery Fuels Buybacks And Dividends?

Why Core Natural Resources Stock Is Back on Investors’ Radar Core Natural Resources (CNR) drew fresh attention today after reporting second quarter 2026 results that showed higher sales, a move back to net income, a quarterly dividend, and progress on its ongoing share repurchase program. See our latest analysis for Core Natural Resources. The strong second quarter update, dividend declaration, and confirmation of 2026 sales guidance have coincided with a sharp shift in sentiment toward Core...
NYSE:HHH
NYSE:HHHReal Estate

Howard Hughes Holdings (HHH) Stock Price And Intrinsic Value Clash After Q2

Howard Hughes Holdings stock jumped about 3.6% to around US$68 after the Q2 print, even though the shares are still down roughly 7.9% over the past month. The market is reacting to a headline quarter that combined a sharp revenue increase to about US$1.1b with a clear message. The real story was not a single-quarter beat or miss. It was management emphasizing a long-horizon plan that uses its real estate cash flows and a growing insurance platform to reshape how investors should think about...
NasdaqGS:LAB
NasdaqGS:LABLife Sciences

Standard BioTools (LAB) Stock Rebound Leaves Revenue Slide And Losses In Focus

Standard BioTools stock inched up about 3% to roughly US$0.80 after earnings, a small bounce that sits awkwardly against a longer slide of more than 20% over the past three months. The headline is not growth. It is the size and persistence of the losses. Q2 revenue came in around US$20.1m while the company reported a net loss from continuing operations over the past year of roughly US$53.9m. For anyone thinking beyond today’s tick higher, the key debate is whether that loss profile can...
NYSE:CPAY
NYSE:CPAYDiversified Financial

Corpay (CPAY) Stock Shrugs Off Record Cash EPS And Higher Outlook

Corpay stock barely flinched after earnings, up less than 1% to about $398, even as the company posted one of its cleanest quarters in recent memory. The market mood looks cautious while the numbers tell a stronger story. The headline is simple. Revenue reached about $1.34b and cash earnings per share hit a record $7 in the quarter. Management lifted full year cash EPS and revenue guidance. With the stock already up double digits over the past month, today’s muted move hints more at investors...
NasdaqGS:NTRA
NasdaqGS:NTRABiotechs

Natera (NTRA) Posted Strong Q2 Results, Is The Stock Fully Priced?

Natera (NTRA) is back in focus after reporting Q2 2026 earnings on August 6, with revenue of US$752.75 million and a narrower net loss, alongside fresh regulatory progress for Signatera in Japan. See our latest analysis for Natera. Natera’s share price has eased in the short term, with a 1-month share price return of down 5.65% and a 7-day share price return of down 1.59%. Momentum over longer periods remains strong, reflected in a 90-day share price return of 36.62% and a 1-year total...
NasdaqGS:DUOL
NasdaqGS:DUOLConsumer Services

Duolingo (DUOL) Stock Drops As Monetization Lags User Growth

Duolingo just handed investors a sentiment test. The stock dropped about 9% today to US$122.58, even though the quarter featured solid revenue of US$298.454m and positive basic earnings per share of US$0.71. The market is reacting as if the growth story has cracked. The financials point to something more nuanced. Coming into this print, Duolingo had already cooled off in the short term, with shares down over the past week and month, while still positive over the past quarter. Today’s move is...
NasdaqGS:ARQT
NasdaqGS:ARQTBiotechs

Arcutis Biotherapeutics (ARQT) Stock Profit Turn Faces ZORYVE Concentration Question

Arcutis Biotherapeutics slipped about 2.5% today to US$26.43, even though the company just turned in what many biotech investors look for most. The dermatology specialist posted Q2 net product revenue of US$129.9m and reported US$15m of net income. That short term pullback sits against a bigger picture of rising revenue guidance for 2026 and a stock that had gained roughly 25% over the past three months. The rest of this earnings breakdown focuses on how durable that profit turn and growth...